newsfilter
← Latest News
GlobeNewswire·

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system